| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.40M | 515.00K | 10.96M | 299.00K | 15.64M | 6.14M |
| Gross Profit | 1.25M | -1.11M | 8.97M | -101.00K | 13.64M | 3.13M |
| EBITDA | -12.37M | -16.21M | -6.41M | -16.02M | 838.00K | -4.94M |
| Net Income | -13.00M | -16.61M | -7.02M | -16.75M | 409.00K | -5.81M |
Balance Sheet | ||||||
| Total Assets | 17.44M | 18.71M | 34.13M | 37.77M | 51.22M | 10.84M |
| Cash, Cash Equivalents and Short-Term Investments | 11.71M | 11.91M | 26.67M | 29.65M | 43.30M | 3.33M |
| Total Debt | 3.03M | 3.08M | 3.16M | 2.91M | 3.61M | 3.39M |
| Total Liabilities | 4.93M | 5.25M | 5.79M | 5.49M | 6.10M | 6.36M |
| Stockholders Equity | 12.51M | 13.46M | 28.34M | 32.28M | 45.12M | 4.48M |
Cash Flow | ||||||
| Free Cash Flow | -10.75M | -14.58M | -3.72M | -15.01M | 912.00K | -4.97M |
| Operating Cash Flow | -10.54M | -14.09M | -2.76M | -13.70M | 2.50M | -4.45M |
| Investing Cash Flow | -209.05K | -539.00K | -1.16M | 28.92M | -31.56M | -519.00K |
| Financing Cash Flow | 3.12M | 9.00K | 1.11M | 1.87M | 38.76M | 4.46M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $26.13M | ― | -127.48% | ― | -95.87% | 35.25% | |
46 Neutral | $27.90M | -4.73 | ― | ― | ― | ― | |
44 Neutral | $26.65M | ― | -88.27% | ― | ― | 32.57% | |
41 Neutral | $32.41M | -0.90 | -312.77% | ― | ― | 61.18% | |
40 Underperform | $28.74M | -2.02 | -78.25% | ― | 248.62% | 26.22% | |
30 Underperform | $29.28M | ― | ― | ― | ― | 31.09% |
On October 20, 2025, CollPlant Biotechnologies announced positive results from a study conducted by the Technion – Israel Institute of Technology, which demonstrated that its rhCollagen-based bioink, Collink.3D™, outperformed Matrigel® in supporting structured tissue formation. This suggests that Collink.3D™ could serve as a next-generation, animal-free extracellular matrix for advanced tissue engineering and research applications, potentially impacting the market for basement membrane matrices, which is projected to grow significantly by 2031.
On October 16, 2025, CollPlant Biotechnologies announced the development of a first-of-its-kind fully humanized 3D bioprinted human skin model by Mayo Clinic researchers, utilizing CollPlant’s rhCollagen-based bioink. This model, which serves as an alternative to animal testing, has significant implications for cosmetic and pharmaceutical testing, disease modeling, and drug development, offering a sustainable and ethical solution while advancing regenerative medicine.
On September 30, 2025, CollPlant Biotechnologies announced positive results from non-clinical studies of its photocurable regenerative dermal and soft tissue filler. This product, which combines hyaluronic acid with a modified form of rhCollagen, is designed to offer both immediate and long-lasting benefits in aesthetic medicine. The successful completion of these studies marks a significant milestone for CollPlant as it prepares to advance the filler into clinical trials, potentially redefining standards in aesthetic treatments by integrating contouring precision, structural support, and tissue regeneration.
On September 15, 2025, CollPlant Biotechnologies announced the expansion of its European distribution network for its VergenixSTR product by signing a new agreement in Poland. VergenixSTR, a soft tissue repair matrix designed to treat tendinopathy, combines rhCollagen with platelet-rich plasma to promote tendon healing. This expansion is part of CollPlant’s strategy to broaden its global distribution network, enhancing its market presence in Europe and the Asia-Pacific region.
CollPlant Biotechnologies Ltd. announced that it has successfully transferred the listing of its ordinary shares from the Nasdaq Global Market to the Nasdaq Capital Market, effective September 12, 2025. This move is part of the company’s strategic efforts to optimize its market positioning while maintaining the trading symbol ‘CLGN’. The transfer is expected to have no impact on the trading of its shares, ensuring continuity for investors and stakeholders.
On August 20, 2025, CollPlant Biotechnologies reported its financial results for the second quarter of 2025, highlighting significant advancements in its photocurable dermal filler program and regenerative breast implant technology. The company is preparing for clinical studies of its dermal filler, which has shown promising results in preclinical testing, and is expanding its market presence with new appointments and collaborations. CollPlant also reported a decrease in GAAP revenues for the quarter compared to the previous year, but an increase in revenues for the first half of the year due to a milestone payment from AbbVie. The company’s efforts to expand its product distribution and enhance its market position in the regenerative medicine industry are ongoing, with a focus on non-animal-derived collagen solutions.